Trilaciclib combined with immunotherapy and chemotherapy for treatment of advanced esophageal cancer:a case report and literature review
YAN Jing-ze
CHEN Hui
GE Xiao-lin
XIA Xiao-jie
Abstract：Immunotherapy combined with chemotherapy has been established as the standard first-line treatment in advanced esophageal cancer(EC).Myelosuppression is the most common side effects of chemotherapy,and severe myelosuppression often leads to prolonged cycles of chemotherapy and reduced doses of chemotherapy,thereby reducing the intensity and potential anti-tumor efficacy of chemotherapy.At present,granulocyte-stimulating factor(G-CSF)is widely used to stimulate the differentiation of bone marrow hematopoietic progenitor cells to treat chemotherapy-induced myelosuppression(CIM).Trilaciclib is a short-acting and reversible CDK4/6 inhibitor,which can provide systemic protection of bone marrow hematopoiesis,and was approved by NMPA in July 2022 for the prophylactic treatment of myelosuppression in extensive-stage small cell lung cancer(ES-SCLC).However,trilaciclib has not been widely used in clinical practice.Therefore,this paper reports a case of one patient with advanced EC who was treated by trilaciclib to prevent CIM in our department,aiming to provide further reference and basis for further investigation.
Keywords：esophageal cancerchemotherapytrilaciclibmyelosuppressionbone marrow protection
Publication Date：2023-12-15
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：5( 2370-2374 )